United Therapeutics (UTHR) closed at $588.61 on November 10, 2026, up 1.1% from the previous close, on volume of 359,394 shares (30-day average 771,462).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Iron Condor or Double Vertical | 16-Oct-26430 P : 460 P : 540 C : 570 C | 33,200 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
Business Wire (Mon, 9-Nov 7:00 AM ET)
United Therapeutics Announces Buydown of Ralinepag Royalty
Business Wire (Wed, 4-Nov 7:00 AM ET)
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 6:30 AM ET)
Business Wire (Wed, 28-Oct 7:00 AM ET)
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Business Wire (Thu, 22-Oct 7:00 AM ET)
Business Wire (Wed, 21-Oct 7:00 AM ET)
Business Wire (Tue, 20-Oct 7:00 AM ET)
Business Wire (Mon, 19-Oct 7:00 AM ET)
Globe Newswire (Tue, 13-Oct 5:44 PM ET)
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
Business Wire (Tue, 13-Oct 7:00 AM ET)
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
United Therapeutics trades on the NASDAQ stock market under the symbol UTHR.
As of November 10, 2026, UTHR stock price climbed to $588.61 with 359,394 million shares trading.
UTHR has a beta of 0.36, meaning it tends to be less sensitive to market movements. UTHR has a correlation of 0.02 to the broad based SPY ETF.
UTHR has a market cap of $25.25 billion. This is considered a Large Cap stock.
Last quarter United Therapeutics reported $832 million in Revenue and $5.71 earnings per share. This beat revenue expectation by $51 million and missed earnings estimates by -$.29.
In the last 3 years, UTHR traded as high as $614.23 and as low as $208.62.
The top ETF exchange traded funds that UTHR belongs to (by Net Assets): IJH, VTI, VB, VXF, MDY.
UTHR has outperformed the market in the last year with a price return of +29.7% while the SPY ETF gained +11.2%. UTHR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.1% and -0.4%, respectively, while the SPY returned -2.7% and -2.6%, respectively.
UTHR support price is $571.24 and resistance is $593.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UTHR shares will trade within this expected range on the day.
